Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Parkinson's Disease

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 219 articles:
HTML format
Text format



Single Articles


    June 2018
  1. DE PABLO-FERNANDEZ E, Goldacre R, Pakpoor J, Noyce AJ, et al
    Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study.
    Neurology. 2018 Jun 13. pii: WNL.0000000000005771.
    PubMed     Text format     Abstract available


    May 2018
  2. CHEN H
    Author response: Olfaction and incident Parkinson disease in US white and black older adults.
    Neurology. 2018;90:941.
    PubMed     Text format    


  3. MAHLKNECHT P, Kiechl S, Willeit J, Poewe W, et al
    Reader response: Olfaction and incident Parkinson disease in US white and black older adults.
    Neurology. 2018;90:940.
    PubMed     Text format    


  4. ALCAUSKAS M, Galetta S
    Editors' note: Olfaction and incident Parkinson disease in US white and black older adults.
    Neurology. 2018;90:940.
    PubMed     Text format    


  5. BOOT E, Butcher NJ, Udow S, Marras C, et al
    Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2.
    Neurology. 2018 May 11. pii: WNL.0000000000005660.
    PubMed     Text format     Abstract available


  6. GROSS A, Racette BA, Camacho-Soto A, Dube U, et al
    Use of medical care biases associations between Parkinson disease and other medical conditions.
    Neurology. 2018 May 9. pii: WNL.0000000000005678.
    PubMed     Text format     Abstract available


  7. PALMA JA, Mano T
    Central or peripheral autonomic dysfunction in Parkinson disease: Does it matter?
    Neurology. 2018 May 4. pii: WNL.0000000000005624.
    PubMed     Text format    


    April 2018
  8. FERREIRA JJ, Lees AJ, Poewe W, Rascol O, et al
    Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005557.
    PubMed     Text format     Abstract available


  9. FULLARD ME, Willis AW
    Author response: Utilization of rehabilitation therapy services in Parkinson disease in the United States.
    Neurology. 2018;90:813.
    PubMed     Text format    


  10. BRYANT MS, Protas EJ
    Reader response: Utilization of rehabilitation therapy services in Parkinson disease in the United States.
    Neurology. 2018;90:812.
    PubMed     Text format    


  11. KARAM C, Galetta S
    Editors' note: Utilization of rehabilitation therapy services in Parkinson disease in the United States.
    Neurology. 2018;90:812.
    PubMed     Text format    


  12. GARDNER RC, Byers AL, Barnes DE, Li Y, et al
    Mild TBI and risk of Parkinson disease: A Chronic Effects of Neurotrauma Consortium Study.
    Neurology. 2018 Apr 18. pii: WNL.0000000000005522.
    PubMed     Text format     Abstract available


  13. ROOS E, Grotta A, Yang F, Bellocco R, et al
    Body mass index, sitting time, and risk of Parkinson disease.
    Neurology. 2018;90:e1413-e1417.
    PubMed     Text format     Abstract available


  14. KIM IY, O'Reilly EJ, Hughes KC, Gao X, et al
    Integration of risk factors for Parkinson disease in 2 large longitudinal cohorts.
    Neurology. 2018 Apr 11. pii: WNL.0000000000005473.
    PubMed     Text format     Abstract available


  15. PAGANO G, Polychronis S, Wilson H, Giordano B, et al
    Diabetes mellitus and Parkinson disease.
    Neurology. 2018 Apr 6. pii: WNL.0000000000005475.
    PubMed     Text format     Abstract available


  16. DAS RR, Unger MM
    Diabetes and Parkinson disease: A sweet spot?
    Neurology. 2018 Apr 6. pii: WNL.0000000000005470.
    PubMed     Text format    


  17. BARRETT MJ, Blair JC, Sperling SA, Smolkin ME, et al
    Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease.
    Neurology. 2018 Apr 4. pii: WNL.0000000000005421.
    PubMed     Text format     Abstract available


  18. KOO BB, Chow CA, Shah DR, Khan FH, et al
    Demoralization in Parkinson disease.
    Neurology. 2018 Apr 4. pii: WNL.0000000000005425.
    PubMed     Text format     Abstract available


  19. BOHNEN NI, Teipel SJ
    Cholinergic forebrain density loss in Parkinson disease: More than just cognitive changes.
    Neurology. 2018 Apr 4. pii: WNL.0000000000005408.
    PubMed     Text format    


    March 2018
  20. BOLLAND MJ, Avenell A, Gamble G, Grey A, et al
    Reader response: Expression of Concern: Does compensatory hyperparathyroidism predispose to ischemic stroke? Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy; An alternative to vitamin D supplementation to
    Neurology. 2018;90:627-628.
    PubMed     Text format    


  21. KARAM C, Galetta S
    Editors' note: Expression of Concern: Does compensatory hyperparathyroidism predispose to ischemic stroke? Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy; An alternative to vitamin D supplementation to p
    Neurology. 2018;90:627.
    PubMed     Text format    


  22. ROY HA, Aziz TZ, Fitzgerald JJ, Green AL, et al
    Beta oscillations and urinary voiding in Parkinson disease.
    Neurology. 2018 Mar 23. pii: WNL.0000000000005355.
    PubMed     Text format     Abstract available


  23. FRATTINI E, Monfrini E, Bitetto G, Ferrari B, et al
    Clinical Reasoning: A 75-year-old man with parkinsonism, mood depression, and weight loss.
    Neurology. 2018;90:572-575.
    PubMed     Text format    


  24. BRODSKY M, Lahna D, Pollock J, Pettersson D, et al
    Nigrosome 1 absence in de novo Parkinson disease.
    Neurology. 2018;90:522-523.
    PubMed     Text format    


    February 2018
  25. DIRKX MF, Zach H, Bloem BR, Hallett M, et al
    The nature of postural tremor in Parkinson disease.
    Neurology. 2018 Feb 23. pii: WNL.0000000000005215.
    PubMed     Text format     Abstract available


  26. HASSAN A
    No handshake agreement on postural tremor subtypes in Parkinson disease?
    Neurology. 2018 Feb 23. pii: WNL.0000000000005199.
    PubMed     Text format    


  27. PILOTTO A, Premi E, Paola Caminiti S, Presotto L, et al
    Single-subject SPM FDG-PET patterns predict risk of dementia progression in Parkinson disease.
    Neurology. 2018 Feb 16. pii: WNL.0000000000005161.
    PubMed     Text format     Abstract available


  28. WEISS D, Massano J
    Approaching adaptive control in neurostimulation for Parkinson disease: Autopilot on.
    Neurology. 2018 Feb 14. pii: WNL.0000000000005111.
    PubMed     Text format    


  29. ARLOTTI M, Marceglia S, Foffani G, Volkmann J, et al
    Eight-hours adaptive deep brain stimulation in patients with Parkinson disease.
    Neurology. 2018 Feb 14. pii: WNL.0000000000005121.
    PubMed     Text format     Abstract available


  30. HONMA M, Masaoka Y, Kuroda T, Futamura A, et al
    Impairment of cross-modality of vision and olfaction in Parkinson disease.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005110.
    PubMed     Text format     Abstract available


    January 2018
  31. MURATA M, Odawara T, Hasegawa K, Iiyama S, et al
    Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized, double-blind phase 2 study.
    Neurology. 2018 Jan 24. pii: WNL.0000000000005010.
    PubMed     Text format     Abstract available


  32. HERSHEY LA, Irwin DJ
    Zonisamide for DLB parkinsonism: An old drug used in a new context.
    Neurology. 2018 Jan 24. pii: WNL.0000000000005006.
    PubMed     Text format    


  33. LEE PC, Ahmed I, Loriot MA, Mulot C, et al
    Smoking and Parkinson disease: Evidence for gene-by-smoking interactions.
    Neurology. 2018 Jan 19. pii: WNL.0000000000004953.
    PubMed     Text format     Abstract available


  34. DAVIS JL, Kurek JA, Morgan JC, Sethi KD, et al
    Teaching Video NeuroImages: Oculogyric crisis in treated Parkinson disease.
    Neurology. 2018;90:e263.
    PubMed     Text format    


  35. MUNOZ DG, Fujioka S
    Caffeine and Parkinson disease: A possible diagnostic and pathogenic breakthrough.
    Neurology. 2018 Jan 3. pii: WNL.0000000000004898.
    PubMed     Text format    


  36. FUJIMAKI M, Saiki S, Li Y, Kaga N, et al
    Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease.
    Neurology. 2018 Jan 3. pii: WNL.0000000000004888.
    PubMed     Text format     Abstract available


    December 2017
  37. BARTHEL C, Nonnekes J, van Helvert M, Haan R, et al
    The laser shoes: A new ambulatory device to alleviate freezing of gait in Parkinson disease.
    Neurology. 2017 Dec 20. pii: WNL.0000000000004795.
    PubMed     Text format     Abstract available


  38. ROSSO AL, Bohnen NI, Launer LJ, Aizenstein HJ, et al
    Vascular and dopaminergic contributors to mild parkinsonian signs in older adults.
    Neurology. 2017 Dec 15. pii: WNL.0000000000004842.
    PubMed     Text format     Abstract available


  39. MELE B, Holroyd-Leduc J, Smith EE, Pringsheim T, et al
    Detecting anxiety in individuals with Parkinson disease: A systematic review.
    Neurology. 2017 Dec 6. pii: WNL.0000000000004771.
    PubMed     Text format     Abstract available


  40. FERRER P, Montoya J, Garcia Ruiz PJ
    Teaching NeuroImages: A rare case of giant perivascular spaces in the midbrain manifesting as atypical parkinsonism.
    Neurology. 2017;89:e272-e273.
    PubMed     Text format    


  41. BROCKMANN K, Lerche S, Dilger SS, Stirnkorb JG, et al
    SNPs in Abeta clearance proteins: Lower CSF Abeta1-42 levels and earlier onset of dementia in PD.
    Neurology. 2017;89:2335-2340.
    PubMed     Text format     Abstract available


  42. DAHODWALA N, Shah K, He Y, Wu SS, et al
    Sex disparities in access to caregiving in Parkinson disease.
    Neurology. 2017 Dec 1. pii: WNL.0000000000004764.
    PubMed     Text format     Abstract available


    November 2017
  43. CENTI J, Freeman R, Gibbons CH, Neargarder S, et al
    Author response: Effects of orthostatic hypotension on cognition in Parkinson disease.
    Neurology. 2017;89:2122.
    PubMed     Text format    


  44. GUARALDI P, Poda R, Calandra-Buonaura G, Solieri L, et al
    Letter re: Effects of orthostatic hypotension on cognition in Parkinson disease.
    Neurology. 2017;89:2122.
    PubMed     Text format    


  45. DODEL R
    beta-Amyloid pathology and Parkinson disease.
    Neurology. 2017 Nov 8. pii: 10.1212/WNL.0000000000004756.
    PubMed     Text format    


  46. WHITWELL JL, Weigand SD, Duffy JR, Clark HM, et al
    Predicting clinical decline in progressive agrammatic aphasia and apraxia of speech.
    Neurology. 2017 Nov 1. pii: 10.1212/WNL.0000000000004685.
    PubMed     Text format     Abstract available


    October 2017
  47. CUMMING K, Macleod AD, Myint PK, Counsell CE, et al
    Early weight loss in parkinsonism predicts poor outcomes: Evidence from an incident cohort study.
    Neurology. 2017 Oct 27. pii: 10.1212/WNL.0000000000004691.
    PubMed     Text format     Abstract available


  48. MOLLENHAUER B, Caspell-Garcia CJ, Coffey CS, Taylor P, et al
    Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.
    Neurology. 2017 Oct 13. pii: 10.1212/WNL.0000000000004609.
    PubMed     Text format     Abstract available


  49. UC EY, Rizzo M, O'Shea AMJ, Anderson SW, et al
    Longitudinal decline of driving safety in Parkinson disease.
    Neurology. 2017 Oct 11. pii: 10.1212/WNL.0000000000004629.
    PubMed     Text format     Abstract available


  50. TABUAS-PEREIRA M, Santana I, Santo GC
    Clinical Reasoning: A 55-year-old man with rapidly progressive dementia and parkinsonism.
    Neurology. 2017;89:e182-e187.
    PubMed     Text format    


  51. BRODSKY MA, Anderson S, Murchison C, Seier M, et al
    Clinical outcomes of asleep vs awake deep brain stimulation for Parkinson disease.
    Neurology. 2017 Oct 6. pii: 10.1212/WNL.0000000000004630.
    PubMed     Text format     Abstract available


  52. AZIZ TZ, Hariz M
    To sleep or not to sleep during deep brain stimulation surgery for Parkinson disease?
    Neurology. 2017 Oct 6. pii: 10.1212/WNL.0000000000004635.
    PubMed     Text format    


    September 2017
  53. LEEHEY M, Luo S, Sharma S, Wills AA, et al
    Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores.
    Neurology. 2017 Sep 29. pii: 10.1212/WNL.0000000000004572.
    PubMed     Text format     Abstract available


  54. HEDERA P, Davis TL
    Can lifestyle modification slow progression of Parkinson disease?
    Neurology. 2017 Sep 29. pii: 10.1212/WNL.0000000000004580.
    PubMed     Text format    


  55. POSTUMA RB, Anang J, Pelletier A, Joseph L, et al
    Caffeine as symptomatic treatment for Parkinson disease (Cafe-PD): A randomized trial.
    Neurology. 2017 Sep 27. pii: 10.1212/WNL.0000000000004568.
    PubMed     Text format     Abstract available


  56. MOREAU C, Barton BR, Devos D
    Virtually reducing fall risk in Parkinson disease.
    Neurology. 2017 Sep 27. pii: 10.1212/WNL.0000000000004581.
    PubMed     Text format    


  57. MAIDAN I, Rosenberg-Katz K, Jacob Y, Giladi N, et al
    Disparate effects of training on brain activation in Parkinson disease.
    Neurology. 2017 Sep 27. pii: 10.1212/WNL.0000000000004576.
    PubMed     Text format     Abstract available


  58. THORMANN A, Sorensen PS, Koch-Henriksen N, Laursen B, et al
    Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality.
    Neurology. 2017 Sep 20. pii: 10.1212/WNL.0000000000004508.
    PubMed     Text format     Abstract available


  59. SHAMIR R, Klein C, Amar D, Vollstedt EJ, et al
    Analysis of blood-based gene expression in idiopathic Parkinson disease.
    Neurology. 2017 Sep 15. pii: 10.1212/WNL.0000000000004516.
    PubMed     Text format     Abstract available


  60. LECLAIR-VISONNEAU L, Clairembault T, Coron E, Le Dily S, et al
    REM sleep behavior disorder is related to enteric neuropathology in Parkinson disease.
    Neurology. 2017 Sep 8. pii: 10.1212/WNL.0000000000004496.
    PubMed     Text format     Abstract available


  61. BOWMAN GL
    Biomarkers for early detection of Parkinson disease: A scent of consistency with olfactory dysfunction.
    Neurology. 2017 Sep 6. pii: 10.1212/WNL.0000000000004383.
    PubMed     Text format    


  62. CHEN H, Shrestha S, Huang X, Jain S, et al
    Olfaction and incident Parkinson disease in US white and black older adults.
    Neurology. 2017 Sep 6. pii: 10.1212/WNL.0000000000004382.
    PubMed     Text format     Abstract available


  63. SEARLES NIELSEN S, Warden MN, Camacho-Soto A, Willis AW, et al
    A predictive model to identify Parkinson disease from administrative claims data.
    Neurology. 2017 Sep 1. pii: 10.1212/WNL.0000000000004536.
    PubMed     Text format     Abstract available


    August 2017
  64. FULLARD ME, Thibault DP, Hill A, Fox J, et al
    Utilization of rehabilitation therapy services in Parkinson disease in the United States.
    Neurology. 2017 Aug 23. pii: 10.1212/WNL.0000000000004355.
    PubMed     Text format     Abstract available


  65. NOLANO M, Provitera V, Manganelli F, Iodice R, et al
    Loss of cutaneous large and small fibers in naive and l-dopa-treated PD patients.
    Neurology. 2017;89:776-784.
    PubMed     Text format     Abstract available


  66. SHPRECHER DR, Majersik JJ
    The virtual house call: A 21st-century innovation in the care of patients with Parkinson disease.
    Neurology. 2017 Aug 16. pii: 10.1212/WNL.0000000000004366.
    PubMed     Text format    


  67. BECK CA, Beran DB, Biglan KM, Boyd CM, et al
    National randomized controlled trial of virtual house calls for Parkinson disease.
    Neurology. 2017 Aug 16. pii: 10.1212/WNL.0000000000004357.
    PubMed     Text format     Abstract available


  68. VERHAGEN METMAN L, Espay AJ
    Teaching Video NeuroImages: The underrecognized diphasic dyskinesia of Parkinson disease.
    Neurology. 2017;89:e83-e84.
    PubMed     Text format    


  69. CURY RG, Fraix V, Castrioto A, Perez Fernandez MA, et al
    Thalamic deep brain stimulation for tremor in Parkinson disease, essential tremor, and dystonia.
    Neurology. 2017 Aug 2. pii: 10.1212/WNL.0000000000004295.
    PubMed     Text format     Abstract available


    July 2017
  70. REGENSBURGER M, Turk M, Pagenstecher A, Schroder R, et al
    VCP-related multisystem proteinopathy presenting as early-onset Parkinson disease.
    Neurology. 2017 Jul 19. pii: 10.1212/WNL.0000000000004240.
    PubMed     Text format    


  71. IRANZO A, Stefani A, Serradell M, Marti MJ, et al
    Characterization of patients with longstanding idiopathic REM sleep behavior disorder.
    Neurology. 2017;89:242-248.
    PubMed     Text format     Abstract available


  72. JACOVA C, Factor SA
    Phosphodiesterase 4: Rethinking cognition in Parkinson disease.
    Neurology. 2017 Jul 12. pii: 10.1212/WNL.0000000000004221.
    PubMed     Text format    


  73. NICCOLINI F, Wilson H, Pagano G, Coello C, et al
    Loss of phosphodiesterase 4 in Parkinson disease: Relevance to cognitive deficits.
    Neurology. 2017 Jul 12. pii: 10.1212/WNL.0000000000004201.
    PubMed     Text format     Abstract available


  74. SIERRA M, Martinez-Rodriguez I, Sanchez-Juan P, Gonzalez-Aramburu I, et al
    Prospective clinical and DaT-SPECT imaging in premotor LRRK2 G2019S-associated Parkinson disease.
    Neurology. 2017 Jul 5. pii: 10.1212/WNL.0000000000004185.
    PubMed     Text format     Abstract available


  75. CILIA R, Laguna J, Cassani E, Cereda E, et al
    Mucuna pruriens in Parkinson disease: A double-blind, randomized, controlled, crossover study.
    Neurology. 2017 Jul 5. pii: 10.1212/WNL.0000000000004175.
    PubMed     Text format     Abstract available



  76. Decrease in Abeta42 predicts dopa-resistant gait progression in early Parkinson disease.
    Neurology. 2017;89:107.
    PubMed     Text format    


    June 2017
  77. HUGHES KC, Gao X, Kim IY, Wang M, et al
    Intake of dairy foods and risk of Parkinson disease.
    Neurology. 2017 Jun 8. pii: 10.1212/WNL.0000000000004057.
    PubMed     Text format     Abstract available


  78. RAJPUT AH, Rajput ML, Ferguson LW, Rajput A, et al
    Baseline motor findings and Parkinson disease prognostic subtypes.
    Neurology. 2017 Jun 7. pii: 10.1212/WNL.0000000000004078.
    PubMed     Text format     Abstract available


    May 2017
  79. MARKOVIC V, Agosta F, Canu E, Inuggi A, et al
    Role of habenula and amygdala dysfunction in Parkinson disease patients with punding.
    Neurology. 2017 May 10. pii: 10.1212/WNL.0000000000004012.
    PubMed     Text format     Abstract available


  80. STOCCHI F, Rascol O, Hauser RA, Huyck S, et al
    Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.
    Neurology. 2017 May 10. pii: 10.1212/WNL.0000000000004003.
    PubMed     Text format     Abstract available


    April 2017
  81. LIU B, Fang F, Pedersen NL, Tillander A, et al
    Vagotomy and Parkinson disease: A Swedish register-based matched-cohort study.
    Neurology. 2017 Apr 26. pii: 10.1212/WNL.0000000000003961.
    PubMed     Text format     Abstract available


  82. BORGHAMMER P, Hamani C
    Preventing Parkinson disease by vagotomy: Fact or fiction?
    Neurology. 2017 Apr 26. pii: 10.1212/WNL.0000000000003969.
    PubMed     Text format    


    March 2017
  83. PAKPOOR J, Noyce A, Goldacre R, Selkihova M, et al
    Viral hepatitis and Parkinson disease: A national record-linkage study.
    Neurology. 2017 Mar 29. pii: 10.1212/WNL.0000000000003848.
    PubMed     Text format     Abstract available


  84. BENITO-LEON J
    Viral hepatitis and the risk of Parkinson disease.
    Neurology. 2017 Mar 29. pii: 10.1212/WNL.0000000000003853.
    PubMed     Text format    


  85. ROCHESTER L, Galna B, Lord S, Yarnall AJ, et al
    Decrease in Abeta42 predicts dopa-resistant gait progression in early Parkinson disease.
    Neurology. 2017 Mar 22. pii: 10.1212/WNL.0000000000003840.
    PubMed     Text format     Abstract available


  86. SINGER W, Berini SE, Sandroni P, Fealey RD, et al
    Pure autonomic failure: Predictors of conversion to clinical CNS involvement.
    Neurology. 2017;88:1129-1136.
    PubMed     Text format     Abstract available


  87. NONNEKES J, Janssen S, Bloem BR
    Superficial brain stimulation to overcome freezing of gait in Parkinson disease.
    Neurology. 2017 Mar 15. pii: 10.1212/WNL.0000000000003859.
    PubMed     Text format    


  88. SAARI L, Kivinen K, Gardberg M, Joutsa J, et al
    Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease.
    Neurology. 2017 Mar 10. pii: 10.1212/WNL.0000000000003810.
    PubMed     Text format     Abstract available


    February 2017
  89. BUCHMAN AS, Bennett DA
    Author response: Incident parkinsonism in older adults without Parkinson disease.
    Neurology. 2017;88:920.
    PubMed     Text format    


  90. BOHNEN NI, Muller M
    Letter re: Incident parkinsonism in older adults without Parkinson disease.
    Neurology. 2017;88:920.
    PubMed     Text format    


  91. BUCHMAN AS, Bennett DA
    Author response: Incident parkinsonism in older adults without Parkinson disease.
    Neurology. 2017;88:919-920.
    PubMed     Text format    


  92. MAHLKNECHT P, Kiechl S, Willeit J, Poewe W, et al
    Letter re: Incident parkinsonism in older adults without Parkinson disease.
    Neurology. 2017;88:919.
    PubMed     Text format    


  93. GOLDMAN JG, Bledsoe IO, Merkitch D, Dinh V, et al
    Corpus callosal atrophy and associations with cognitive impairment in Parkinson disease.
    Neurology. 2017 Feb 24. pii: 10.1212/WNL.0000000000003764.
    PubMed     Text format     Abstract available


  94. MERY VP, Gros P, Lafontaine AL, Robinson A, et al
    Reduced cognitive function in patients with Parkinson disease and obstructive sleep apnea.
    Neurology. 2017 Feb 22. pii: 10.1212/WNL.0000000000003738.
    PubMed     Text format     Abstract available


  95. LEWITT PA, Li J, Lu M, Guo L, et al
    Metabolomic biomarkers as strong correlates of Parkinson disease progression.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003663.
    PubMed     Text format     Abstract available


  96. ALVES G, Bonanni L
    Neurofilament light: A heavyweight diagnostic biomarker in neurodegenerative parkinsonism?
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003699.
    PubMed     Text format    


  97. HANSSON O, Janelidze S, Hall S, Magdalinou N, et al
    Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003680.
    PubMed     Text format     Abstract available


    January 2017
  98. EWENCZYK C, Mesmoudi S, Gallea C, Welter ML, et al
    Antisaccades in Parkinson disease: A new marker of postural control?
    Neurology. 2017 Jan 27. pii: 10.1212/WNL.0000000000003658.
    PubMed     Text format     Abstract available


  99. PEDERSEN KF, Larsen JP, Tysnes OB, Alves G, et al
    Natural course of mild cognitive impairment in Parkinson disease: A 5-year population-based study.
    Neurology. 2017 Jan 20. pii: 10.1212/WNL.0000000000003634.
    PubMed     Text format     Abstract available


  100. FEDOROVA TD, Seidelin LB, Knudsen K, Schacht AC, et al
    Decreased intestinal acetylcholinesterase in early Parkinson disease: An 11C-donepezil PET study.
    Neurology. 2017 Jan 18. pii: 10.1212/WNL.0000000000003633.
    PubMed     Text format     Abstract available


  101. KUBU CS, Cooper SE, Machado A, Frazier T, et al
    Insights gleaned by measuring patients' stated goals for DBS: More than tremor.
    Neurology. 2017;88:124-130.
    PubMed     Text format     Abstract available


    December 2016
  102. RACETTE BA, Searles Nielsen S, Criswell SR, Sheppard L, et al
    Dose-dependent progression of parkinsonism in manganese-exposed welders.
    Neurology. 2016 Dec 28. pii: 10.1212/WNL.0000000000003533.
    PubMed     Text format     Abstract available


  103. RATNER MH, Fitzgerald E
    Understanding of the role of manganese in parkinsonism and Parkinson disease.
    Neurology. 2016 Dec 28. pii: 10.1212/WNL.0000000000003543.
    PubMed     Text format    


  104. THOLFSEN LK, Larsen JP, Schulz J, Tysnes OB, et al
    Changes in insomnia subtypes in early Parkinson disease.
    Neurology. 2016 Dec 16. pii: 10.1212/WNL.0000000000003540.
    PubMed     Text format     Abstract available


    November 2016
  105. CENTI J, Freeman R, Gibbons CH, Neargarder S, et al
    Effects of orthostatic hypotension on cognition in Parkinson disease.
    Neurology. 2016 Nov 30. pii: 10.1212/WNL.0000000000003452.
    PubMed     Text format     Abstract available


  106. BOYLAN LS, Messinis L
    Orthostatic hypotension, cognition, and Parkinson disease: Dumbing down by standing up.
    Neurology. 2016 Nov 30. pii: 10.1212/WNL.0000000000003468.
    PubMed     Text format    


  107. MANO T, Britton Z, Britton T
    Anatomo-functional basis of nonmotor symptoms in Parkinson disease.
    Neurology. 2016 Nov 16. pii: 10.1212/WNL.0000000000003443.
    PubMed     Text format    


  108. PYATIGORSKAYA N, Mongin M, Valabregue R, Yahia-Cherif L, et al
    Medulla oblongata damage and cardiac autonomic dysfunction in Parkinson disease.
    Neurology. 2016 Nov 11. pii: 10.1212/WNL.0000000000003426.
    PubMed     Text format     Abstract available


  109. PAGANO G, Molloy S, Bain PG, Rabiner EA, et al
    Sleep problems and hypothalamic dopamine D3 receptor availability in Parkinson disease.
    Neurology. 2016 Nov 2. pii: 10.1212/WNL.0000000000003396.
    PubMed     Text format     Abstract available


    October 2016
  110. MATTIS PJ, Niethammer M, Sako W, Tang CC, et al
    Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases.
    Neurology. 2016 Oct 5. pii: 10.1212/WNL.0000000000003285.
    PubMed     Text format     Abstract available


  111. BRYS M, Fox MD, Agarwal S, Biagioni M, et al
    Multifocal repetitive TMS for motor and mood symptoms of Parkinson disease: A randomized trial.
    Neurology. 2016 Oct 5. pii: 10.1212/WNL.0000000000003279.
    PubMed     Text format     Abstract available


    September 2016
  112. UMEMOTO G, Fujioka S, Yanamoto S, Fukae J, et al
    A case of sudden deterioration in Parkinson disease.
    Neurology. 2016;87:1422.
    PubMed     Text format    


  113. MORGANTE F, Fasano A, Ginevrino M, Petrucci S, et al
    Impulsive-compulsive behaviors in parkin-associated Parkinson disease.
    Neurology. 2016 Sep 2. pii: 10.1212/WNL.0000000000003177.
    PubMed     Text format     Abstract available


  114. BJORNESTAD A, Tysnes OB, Larsen JP, Alves G, et al
    Loss of independence in early Parkinson disease: A 5-year population-based incident cohort study.
    Neurology. 2016 Sep 2. pii: 10.1212/WNL.0000000000003213.
    PubMed     Text format     Abstract available


    August 2016
  115. QUATTRONE A, Morelli M, Williams DR, Vescio B, et al
    MR parkinsonism index predicts vertical supranuclear gaze palsy in patients with PSP-parkinsonism.
    Neurology. 2016 Aug 24. pii: 10.1212/WNL.0000000000003125.
    PubMed     Text format     Abstract available


  116. BARICHELLA M, Pacchetti C, Bolliri C, Cassani E, et al
    Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT.
    Neurology. 2016 Aug 19. pii: 10.1212/WNL.0000000000003127.
    PubMed     Text format     Abstract available


  117. SIDIROPOULOS C, LeWitt PA, Odekerken VJ, Schuurman PR, et al
    GPi vs STN deep brain stimulation for Parkinson disease: Three-year follow-up.
    Neurology. 2016;87:745-6.
    PubMed     Text format    


  118. BUCHMAN AS, Leurgans SE, Yu L, Wilson RS, et al
    Incident parkinsonism in older adults without Parkinson disease.
    Neurology. 2016 Aug 3. pii: 10.1212/WNL.0000000000003059.
    PubMed     Text format     Abstract available


    July 2016
  119. BOYD JT, Wangensteen KJ, Krawitt EL, Hamill RW, et al
    Hepatitis C virus infection as a risk factor for Parkinson disease: A nationwide cohort study.
    Neurology. 2016;87:342.
    PubMed     Text format    


  120. BURCIU RG, Chung JW, Shukla P, Ofori E, et al
    Functional MRI of disease progression in Parkinson disease and atypical parkinsonian syndromes.
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000002985.
    PubMed     Text format     Abstract available



  121. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.
    Neurology. 2016;87:239.
    PubMed     Text format    


  122. JELLINGER KA, Logroscino G, Rizzo G, Copetti M, et al
    Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis.
    Neurology. 2016;87:237-8.
    PubMed     Text format    


  123. GIBBONS CH, Garcia J, Wang N, Shih LC, et al
    The diagnostic discrimination of cutaneous alpha-synuclein deposition in Parkinson disease.
    Neurology. 2016 Jul 6. pii: 10.1212/WNL.0000000000002919.
    PubMed     Text format     Abstract available


    June 2016
  124. GOODARZI Z, Mrklas KJ, Roberts DJ, Jette N, et al
    Detecting depression in Parkinson disease: A systematic review and meta-analysis.
    Neurology. 2016 Jun 29. pii: 10.1212/WNL.0000000000002898.
    PubMed     Text format     Abstract available


  125. COLLOBY SJ, McKeith IG, Burn DJ, Wyper DJ, et al
    Cholinergic and perfusion brain networks in Parkinson disease dementia.
    Neurology. 2016 Jun 15. pii: 10.1212/WNL.0000000000002839.
    PubMed     Text format     Abstract available


    May 2016
  126. OSAKI Y, Fujita K, Abe T, Harada M, et al
    Mystery Case: Parkinsonism in a diabetic uremic patient.
    Neurology. 2016;86:e225-7.
    PubMed     Text format    


  127. VAN DER HEEDEN JF, Marinus J, Martinez-Martin P, Rodriguez-Blazquez C, et al
    Postural instability and gait are associated with severity and prognosis of Parkinson disease.
    Neurology. 2016 May 13. pii: 10.1212/WNL.0000000000002768.
    PubMed     Text format     Abstract available


  128. FACTOR SA, Bennett A, Hohler AD, Wang D, et al
    Quality improvement in neurology: Parkinson disease update quality measurement set: Executive summary.
    Neurology. 2016 May 11. pii: 10.1212/WNL.0000000000002670.
    PubMed     Text format    


  129. CHAUDHURI KR
    Progression and biomarkers for Parkinson disease: Merging motor with nonmotor symptoms.
    Neurology. 2016 May 6. pii: 10.1212/WNL.0000000000002664.
    PubMed     Text format    


  130. MOLLENHAUER B, Zimmermann J, Sixel-Doring F, Focke NK, et al
    Monitoring of 30 marker candidates in early Parkinson disease as progression markers.
    Neurology. 2016 May 6. pii: 10.1212/WNL.0000000000002651.
    PubMed     Text format     Abstract available


  131. LATTANZI S, Silvestrini M, Verbeek MM, Mollenhauer B, et al
    Increased CSF biomarkers of angiogenesis in Parkinson disease.
    Neurology. 2016;86:1747-8.
    PubMed     Text format    


    April 2016
  132. BOHNEN NI, Muller ML, Sohn YH, Lee DH, et al
    Is normosmic Parkinson disease a unique clinical phenotype?
    Neurology. 2016;86:1649-50.
    PubMed     Text format    


  133. MASSANO J, Bronstein JM
    Writeclick: Neuropsychological outcome after deep brain stimulation for Parkinson disease.
    Neurology. 2016;86:1563-4.
    PubMed     Text format    


  134. LOVERA LC, Rodriguez-Porcel F, Urrea-Mendoza E, Fasano A, et al
    Flamenco dancer posture: Unique "off" complication in Parkinson disease.
    Neurology. 2016;86:1462-3.
    PubMed     Text format    


  135. LEWITT PA, Fahn S
    Levodopa therapy for Parkinson disease: A look backward and forward.
    Neurology. 2016;86.
    PubMed     Text format     Abstract available


  136. SILVER DE, Trosch RM
    Physicians' experience with RYTARY (carbidopa and levodopa) extended-release capsules in patients who have Parkinson disease.
    Neurology. 2016;86.
    PubMed     Text format     Abstract available


  137. DHALL R, Kreitzman DL
    Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety.
    Neurology. 2016;86.
    PubMed     Text format     Abstract available


  138. GUPTA S
    Advances in levodopa therapy for Parkinson disease.
    Neurology. 2016;86.
    PubMed     Text format    


    March 2016
  139. ABE K, Bohnen NI, Muller ML, van der Holst HM, et al
    Cerebral small vessel disease and incident parkinsonism: The RUN DMC study.
    Neurology. 2016;86:1268-9.
    PubMed     Text format    


  140. BOHNEN NI, Muller ML
    Cerebral small vessel disease and incident parkinsonism: the RUN DMC study.
    Neurology. 2016;86:1268-9.
    PubMed     Text format    


  141. ABE K
    Cerebral small vessel disease and incident parkinsonism: the RUN DMC study.
    Neurology. 2016;86:1268-9.
    PubMed     Text format    



  142. Hepcidin ameliorates mitochondrial damage in a rat model of Parkinson's disease (P3.019).
    Neurology. 2016;86:1077.
    PubMed     Text format    


  143. SCHERFLER C, Gobel G, Muller C, Nocker M, et al
    Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism.
    Neurology. 2016 Mar 2. pii: 10.1212/WNL.0000000000002518.
    PubMed     Text format     Abstract available


    February 2016
  144. ROUSSAKIS AA, Politis M, Towey D, Piccini P, et al
    Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias.
    Neurology. 2016 Feb 26. pii: 10.1212/WNL.0000000000002494.
    PubMed     Text format     Abstract available


  145. VELSEBOER DC, de Bie RM, Wieske L, Evans JR, et al
    Development and external validation of a prognostic model in newly diagnosed Parkinson disease.
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002437.
    PubMed     Text format     Abstract available


  146. CHIO A, Defazio G
    A new scale for prognostication in Parkinson disease: Of animals and men.
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002435.
    PubMed     Text format    


  147. STERLING NW, Wang M, Zhang L, Lee EY, et al
    Stage-dependent loss of cortical gyrification as Parkinson disease "unfolds".
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002492.
    PubMed     Text format     Abstract available


  148. GRUNEWALD A, Klein C
    Urinary LRRK2 phosphorylation: Penetrating the thicket of Parkinson disease?
    Neurology. 2016 Feb 10. pii: 10.1212/WNL.0000000000002438.
    PubMed     Text format    


  149. PAGANO G, Ferrara N, Brooks DJ, Pavese N, et al
    Age at onset and Parkinson disease phenotype.
    Neurology. 2016 Feb 10. pii: 10.1212/WNL.0000000000002461.
    PubMed     Text format     Abstract available


  150. KEMPSTER PA
    Biomarkers for the progression of Parkinson disease.
    Neurology. 2016 Feb 10. pii: 10.1212/WNL.0000000000002473.
    PubMed     Text format    


  151. FRASER KB, Moehle MS, Alcalay RN, West AB, et al
    Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers.
    Neurology. 2016 Feb 10. pii: 10.1212/WNL.0000000000002436.
    PubMed     Text format     Abstract available


  152. ABBOTT RD, Ross GW, Petrovitch H, Masaki KH, et al
    Midlife milk consumption and substantia nigra neuron density at death.
    Neurology. 2016;86:512-9.
    PubMed     Text format     Abstract available


  153. CHEN H, Marder K
    Milk consumption and the risk of nigral degeneration.
    Neurology. 2016;86:496-7.
    PubMed     Text format    


    January 2016
  154. ODEKERKEN VJ, Boel JA, Schmand BA, de Haan RJ, et al
    GPi vs STN deep brain stimulation for Parkinson disease: Three-year follow-up.
    Neurology. 2016 Jan 27. pii: 10.1212/WNL.0000000000002401.
    PubMed     Text format     Abstract available


  155. STOESSL AJ
    Comment: Increased D3 binding-A substrate for levodopa-induced dyskinesias?
    Neurology. 2016;86:228.
    PubMed     Text format    


  156. GAO X, O'Reilly EJ, Schwarzschild MA, Ascherio A, et al
    Prospective study of plasma urate and risk of Parkinson disease in men and women.
    Neurology. 2016 Jan 13. pii: 10.1212/WNL.0000000000002351.
    PubMed     Text format     Abstract available


  157. RIZZO G, Copetti M, Arcuti S, Martino D, et al
    Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis.
    Neurology. 2016 Jan 13. pii: 10.1212/WNL.0000000000002350.
    PubMed     Text format     Abstract available


  158. KOSCHMIDDER E, Weissbach A, Bruggemann N, Kasten M, et al
    A nonsense mutation in CHCHD2 in a patient with Parkinson disease.
    Neurology. 2016 Jan 13. pii: 10.1212/WNL.0000000000002361.
    PubMed     Text format    


    December 2015
  159. PAYER DE, Guttman M, Kish SJ, Tong J, et al
    D3 dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia.
    Neurology. 2015 Dec 30. pii: 10.1212/WNL.0000000000002285.
    PubMed     Text format     Abstract available


  160. LOHLE M, Mende J, Wolz M, Beuthien-Baumann B, et al
    Putaminal dopamine turnover in de novo Parkinson disease predicts later motor complications.
    Neurology. 2015 Dec 30. pii: 10.1212/WNL.0000000000002286.
    PubMed     Text format     Abstract available


  161. TSAI HH, Liou HH, Muo CH, Lee CZ, et al
    Hepatitis C virus infection as a risk factor for Parkinson disease: A nationwide cohort study.
    Neurology. 2015 Dec 23. pii: 10.1212/WNL.0000000000002307.
    PubMed     Text format     Abstract available


  162. HATANO T, Kurita N, Kobayashi M, Hattori N, et al
    Teaching Video NeuroImages: Re-emergent jaw tremor in Parkinson disease.
    Neurology. 2015;85:e181.
    PubMed     Text format    


    November 2015
  163. LABBE C, Ogaki K, Lorenzo-Betancor O, Soto-Ortolaza AI, et al
    Role for the microtubule-associated protein tau variant p.A152T in risk of alpha-synucleinopathies.
    Neurology. 2015;85:1680-6.
    PubMed     Text format     Abstract available


  164. WITJAS T, Carron R, Krack P, Eusebio A, et al
    A prospective single-blind study of Gamma Knife thalamotomy for tremor.
    Neurology. 2015;85:1562-8.
    PubMed     Text format     Abstract available


  165. GOLDSTEIN DS, Holmes C, Sharabi Y, Wu T, et al
    Survival in synucleinopathies: A prospective cohort study.
    Neurology. 2015;85:1554-61.
    PubMed     Text format     Abstract available


    October 2015
  166. VENTURA MI, Edwards JD, Barnes DE
    More than just a movement disorder: Why cognitive training is needed in Parkinson disease.
    Neurology. 2015 Oct 30. pii: 10.1212/WNL.0000000000002158.
    PubMed     Text format    


  167. LEUNG IH, Walton CC, Hallock H, Lewis SJ, et al
    Cognitive training in Parkinson disease: A systematic review and meta-analysis.
    Neurology. 2015 Oct 30. pii: 10.1212/WNL.0000000000002145.
    PubMed     Text format     Abstract available


  168. JANELIDZE S, Lindqvist D, Francardo V, Hall S, et al
    Increased CSF biomarkers of angiogenesis in Parkinson disease.
    Neurology. 2015 Oct 28. pii: 10.1212/WNL.0000000000002151.
    PubMed     Text format     Abstract available


  169. MUNOZ DG, Woulfe JM
    Angiogenesis: A new paradigm for Parkinson disease with practical and pathogenic implications.
    Neurology. 2015 Oct 28. pii: 10.1212/WNL.0000000000002160.
    PubMed     Text format    


  170. TINAZZI M, Fasano A, Geroin C, Morgante F, et al
    Pisa syndrome in Parkinson disease: An observational multicenter Italian study.
    Neurology. 2015 Oct 21. pii: 10.1212/WNL.0000000000002122.
    PubMed     Text format     Abstract available


  171. BRONSTEIN JM, Odekerken VJ, Boel JA, Schmand BA, et al
    Neuropsychological outcome after deep brain stimulation for Parkinson disease.
    Neurology. 2015;85:1433-4.
    PubMed     Text format    


  172. ODEKERKEN VJ, Boel JA, Schmand BA, de Bie RM, et al
    Author response.
    Neurology. 2015;85:1433-4.
    PubMed     Text format    


  173. UNGER MM, Sakakibara R
    Does REM sleep behavior disorder have the guts to be Parkinson disease?
    Neurology. 2015 Oct 16. pii: 10.1212/WNL.0000000000002130.
    PubMed     Text format    


  174. HASSAN A, Benarroch EE
    Heterogeneity of the midbrain dopamine system: Implications for Parkinson disease.
    Neurology. 2015 Oct 16. pii: 10.1212/WNL.0000000000002137.
    PubMed     Text format    


  175. IACONO D, Geraci-Erck M, Rabin ML, Adler CH, et al
    Parkinson disease and incidental Lewy body disease: Just a question of time?
    Neurology. 2015 Oct 14. pii: 10.1212/WNL.0000000000002102.
    PubMed     Text format     Abstract available


  176. VAN DER HOLST HM, van Uden IW, Tuladhar AM, de Laat KF, et al
    Cerebral small vessel disease and incident parkinsonism: The RUN DMC study.
    Neurology. 2015 Oct 7. pii: 10.1212/WNL.0000000000002082.
    PubMed     Text format     Abstract available


  177. LUCA CC, Rundek T
    Parkinsonism, small vessel disease, and white matter disease: Is there a link?
    Neurology. 2015 Oct 7. pii: 10.1212/WNL.0000000000002091.
    PubMed     Text format    


    September 2015
  178. PARK JE
    Reflections: Neurology and the Humanities. Not too late.
    Neurology. 2015;85:e88.
    PubMed     Text format    


  179. PIGOTT K, Rick J, Xie SX, Hurtig H, et al
    Longitudinal study of normal cognition in Parkinson disease.
    Neurology. 2015 Sep 11. pii: 10.1212/WNL.0000000000002001.
    PubMed     Text format     Abstract available


  180. HERSHEY LA, Peavy GM
    Cognitive decline in Parkinson disease: How steep and crowded is the slope?
    Neurology. 2015 Sep 11. pii: 10.1212/WNL.0000000000002003.
    PubMed     Text format    


  181. WANG L, Aasly JO, Annesi G, Bardien S, et al
    Large-scale assessment of polyglutamine repeat expansions in Parkinson disease.
    Neurology. 2015 Sep 9. pii: 10.1212/WNL.0000000000002016.
    PubMed     Text format     Abstract available


  182. ROSSI S, Ulivelli M
    The olfactory side of Parkinson disease: Relevance for clinical practice.
    Neurology. 2015 Sep 9. pii: 10.1212/WNL.0000000000002005.
    PubMed     Text format    


  183. LEE DH, Oh JS, Ham JH, Lee JJ, et al
    Is normosmic Parkinson disease a unique clinical phenotype?
    Neurology. 2015 Sep 9. pii: 10.1212/WNL.0000000000001999.
    PubMed     Text format     Abstract available


  184. FILLA A
    CAG repeats in idiopathic Parkinson disease: To screen or not to screen.
    Neurology. 2015 Sep 9. pii: 10.1212/WNL.0000000000002024.
    PubMed     Text format    


  185. MORTIBOYS H, Furmston R, Bronstad G, Aasly J, et al
    UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S) carriers and in vivo.
    Neurology. 2015;85:846-52.
    PubMed     Text format     Abstract available


  186. HUOT P, Hutchison WD
    Serotonin/dopamine transporter ratio as a predictor of L-dopa-induced dyskinesia.
    Neurology. 2015;85:840-1.
    PubMed     Text format    


  187. RUFFMANN C, Parkkinen L, Woulfe JM, Gray MT, et al
    Colonic mucosal alpha-synuclein lacks specificity as a biomarker for Parkinson disease.
    Neurology. 2015;85:834-5.
    PubMed     Text format    


  188. VISANJI NP, Lang AE, Hazrai LN
    Author response.
    Neurology. 2015;85:834-5.
    PubMed     Text format    


  189. WOULFE JM, Gray MT, Munoz G
    Colonic mucosal alpha-synuclein lacks specificity as a biomarker for Parkinson disease.
    Neurology. 2015;85:834.
    PubMed     Text format    


    August 2015
  190. OOSTERVELD LP, Allen JC Jr, Ng EY, Seah SH, et al
    Greater motor progression in patients with Parkinson disease who carry LRRK2 risk variants.
    Neurology. 2015 Aug 26. pii: 10.1212/WNL.0000000000001953.
    PubMed     Text format     Abstract available


  191. KELLEY JM, Espay AJ, Dwivedi A, Lang AE, et al
    Placebo effect of medication cost in Parkinson disease: A randomized double-blind study.
    Neurology. 2015;85:742-3.
    PubMed     Text format    


  192. KELLEY JM
    Placebo effect of medication cost in Parkinson disease: a randomized double-blind study.
    Neurology. 2015;85:742-3.
    PubMed     Text format    


  193. XIE T, Vigil J, MacCracken E, Warnke P, et al
    Author Response.
    Neurology. 2015;85:557.
    PubMed     Text format    


  194. SIDIROPOULOS C
    Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD.
    Neurology. 2015;85:557.
    PubMed     Text format    


  195. GREENAMYRE JT, Sanders LH, Gasser T
    Fruit flies, bile acids, and Parkinson disease: A mitochondrial connection?
    Neurology. 2015 Aug 7. pii: 10.1212/WNL.0000000000001912.
    PubMed     Text format    


  196. LEE JY, Seo S, Lee JS, Kim HJ, et al
    Putaminal serotonergic innervation: Monitoring dyskinesia risk in Parkinson disease.
    Neurology. 2015 Aug 7. pii: 10.1212/WNL.0000000000001909.
    PubMed     Text format     Abstract available


  197. NIRENBERG MJ
    Preoperative factors of apathy in subthalamic stimulated Parkinson disease: A PET study.
    Neurology. 2015;85:483.
    PubMed     Text format    


  198. WORTHINGTON JM, Ney J
    The end of life with PD can be well-lived: the neurologist's role.
    Neurology. 2015;85:394-5.
    PubMed     Text format    


  199. KOGA S, Aoki N, Uitti RJ, van Gerpen JA, et al
    When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients.
    Neurology. 2015;85:404-12.
    PubMed     Text format     Abstract available


    July 2015
  200. NA YC, Chang WS, Jung HH, Kweon EJ, et al
    Unilateral magnetic resonance-guided focused ultrasound pallidotomy for Parkinson disease.
    Neurology. 2015 Jul 15. pii: 10.1212/WNL.0000000000001826.
    PubMed     Text format    


  201. KIM SJ, Udupa K, Ni Z, Moro E, et al
    Effects of subthalamic nucleus stimulation on motor cortex plasticity in Parkinson disease.
    Neurology. 2015 Jul 8. pii: 10.1212/WNL.0000000000001806.
    PubMed     Text format     Abstract available


  202. MARDER K, Wang Y, Alcalay RN, Mejia-Santana H, et al
    Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium.
    Neurology. 2015;85:89-95.
    PubMed     Text format     Abstract available


  203. SAFARPOUR D, Thibault DP, DeSanto CL, Boyd CM, et al
    Nursing home and end-of-life care in Parkinson disease.
    Neurology. 2015 Jul 2. pii: 10.1212/WNL.0000000000001715.
    PubMed     Text format     Abstract available


  204. XIE T, Guan R, Staisch J, Towle VL, et al
    Respiratory dyskinesia in a patient with Parkinson disease successfully treated with STN DBS.
    Neurology. 2015 Jul 2. pii: 10.1212/WNL.0000000000001809.
    PubMed     Text format    


    June 2015
  205. THOLFSEN LK, Larsen JP, Schulz J, Tysnes OB, et al
    Development of excessive daytime sleepiness in early Parkinson disease.
    Neurology. 2015 Jun 17. pii: 10.1212/WNL.0000000000001737.
    PubMed     Text format     Abstract available


  206. RACETTE BA, Willis AW
    Time to change the blind men and the elephant approach to Parkinson disease?
    Neurology. 2015 Jun 12. pii: 10.1212/WNL.0000000000001739.
    PubMed     Text format     Abstract available


  207. MULLER ML, Albin RL, Bohnen NI, Jennings D, et al
    Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study.
    Neurology. 2015;84:2292.
    PubMed     Text format    


  208. JENNINGS D, Siderowf A, Stern M, Seibyl J, et al
    Author Response.
    Neurology. 2015;84:2292.
    PubMed     Text format    


    May 2015
  209. GUSTAFSSON H, Nordstrom A, Nordstrom P
    Depression and subsequent risk of Parkinson disease: A nationwide cohort study.
    Neurology. 2015 May 20. pii: 10.1212/WNL.0000000000001684.
    PubMed     Text format     Abstract available


  210. BRIDEL C, Garibotto V
    Teaching NeuroImages: Drug-induced parkinsonism with asymmetrical putaminal DaT binding.
    Neurology. 2015;84:e159.
    PubMed     Text format    


  211. MCKEOWN MJ, Peavy GM
    Biomarkers in Parkinson disease: It's time to combine.
    Neurology. 2015 May 15. pii: 10.1212/WNL.0000000000001692.
    PubMed     Text format    


  212. CAMPBELL MC, Koller JM, Snyder AZ, Buddhala C, et al
    CSF proteins and resting-state functional connectivity in Parkinson disease.
    Neurology. 2015 May 15. pii: 10.1212/WNL.0000000000001681.
    PubMed     Text format     Abstract available


    March 2015
  213. WEINTRAUB D, Papay K, Xie SX
    Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study.
    Neurology. 2015;84:1386-7.
    PubMed     Text format    


  214. LIANG JW, Shanker VL, Groves M
    Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study.
    Neurology. 2015;84:1386-7.
    PubMed     Text format    


  215. MASSANO J, Troster AI
    About deep brain stimulation.
    Neurology. 2015;84:e100-1.
    PubMed     Text format    


  216. ANANG JB, Postuma R
    Author response.
    Neurology. 2015;84:1285-6.
    PubMed     Text format    


    February 2015
  217. MACKAY CE, Szewczyk-Krolikowski K, Ben-Shlomo Y, Hu M, et al
    Author response.
    Neurology. 2015;84:546.
    PubMed     Text format    


  218. MONTGOMERY EB JR
    Functional connectivity in the basal ganglia network differentiates PD patients from controls.
    Neurology. 2015;84:546.
    PubMed     Text format    


    January 2015
  219. FUHR P, Zimmermann R, Gschwandtner U
    Author response.
    Neurology. 2015;84:104-5.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: